Amneal enters u.s. biosimilars market with approval of releukotm (filgrastim-ayow)

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced the u.s. food and drug administration (fda) approval of the biologics license application (bla) for filgrastim-ayow, a biosimilar referencing neupogen®. the product will be marketed under the proprietary name releukotm. releukotm was developed in collaboration with kashiv biosciences, llc located in chicago, illinois. it is used to treat neutropenia (low neutrophils which ar
AMRX Ratings Summary
AMRX Quant Ranking